Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis
Key claim: This trial evaluates the efficacy and safety of gecacitinib administered before, during, and after allogeneic HSCT in patients with primary or secondary myelofibrosis.
Abstract
The investigators evaluate the efficacy and safety of Gecacitinib in patients with myelofibrosis (MF) before, during, and after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Why this matters
Extending gecacitinib across the entire peri-transplant continuum tests whether a dual JAK/ACVR1 inhibitor can simultaneously serve as bridging therapy, conditioning adjunct, and GVHD prophylaxis — the same expanded role ruxolitinib has been carving out. If successful, it offers MF transplant candidates a second JAK-pathway option with a differentiated mechanism (ACVR1/hepcidin) that may matter for cytopenic or anemia-predominant phenotypes. The trial directly informs the bridging-strategy and GVHD-prophylaxis decision points for MF allo-HSCT.